Free Trial

Insider Selling: Akebia Therapeutics, Inc. (NASDAQ:AKBA) CFO Sells 41,314 Shares of Stock

Akebia Therapeutics logo with Medical background

Akebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) CFO Erik Ostrowski sold 41,314 shares of the stock in a transaction dated Monday, June 30th. The shares were sold at an average price of $3.67, for a total value of $151,622.38. Following the completion of the transaction, the chief financial officer directly owned 503,586 shares of the company's stock, valued at $1,848,160.62. This represents a 7.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Akebia Therapeutics Stock Performance

Shares of NASDAQ:AKBA traded down $0.03 on Friday, reaching $3.61. 1,565,452 shares of the company's stock were exchanged, compared to its average volume of 3,151,266. The business's 50-day moving average is $3.11 and its two-hundred day moving average is $2.37. The company has a quick ratio of 2.02, a current ratio of 2.23 and a debt-to-equity ratio of 1.89. Akebia Therapeutics, Inc. has a fifty-two week low of $0.91 and a fifty-two week high of $4.08. The firm has a market capitalization of $946.82 million, a price-to-earnings ratio of -17.17 and a beta of 0.88.

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.06. The company had revenue of $57.34 million during the quarter, compared to the consensus estimate of $44.88 million. As a group, equities research analysts forecast that Akebia Therapeutics, Inc. will post -0.3 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently commented on AKBA. Leerink Partners started coverage on Akebia Therapeutics in a research note on Monday, April 28th. They set an "outperform" rating and a $7.00 target price for the company. Wall Street Zen raised shares of Akebia Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, May 3rd. Leerink Partnrs upgraded shares of Akebia Therapeutics to a "strong-buy" rating in a research note on Monday, April 28th. Piper Sandler increased their price target on shares of Akebia Therapeutics from $4.00 to $6.00 and gave the stock an "overweight" rating in a research report on Friday, March 14th. Finally, Jefferies Financial Group assumed coverage on Akebia Therapeutics in a research note on Tuesday, April 1st. They issued a "buy" rating and a $6.00 price target for the company. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Akebia Therapeutics has a consensus rating of "Buy" and an average target price of $6.75.

Read Our Latest Report on AKBA

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AKBA. SRS Capital Advisors Inc. bought a new stake in shares of Akebia Therapeutics during the fourth quarter valued at about $26,000. PDS Planning Inc acquired a new stake in shares of Akebia Therapeutics in the fourth quarter valued at $28,000. Mariner LLC acquired a new stake in shares of Akebia Therapeutics in the fourth quarter valued at $28,000. Unified Investment Management boosted its stake in Akebia Therapeutics by 47.8% during the first quarter. Unified Investment Management now owns 17,000 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 5,500 shares in the last quarter. Finally, Cibc World Markets Corp acquired a new position in Akebia Therapeutics during the fourth quarter worth about $37,000. Institutional investors own 33.92% of the company's stock.

About Akebia Therapeutics

(Get Free Report)

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.

Read More

Should You Invest $1,000 in Akebia Therapeutics Right Now?

Before you consider Akebia Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Akebia Therapeutics wasn't on the list.

While Akebia Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines